United Therapeutics (UTHR) Long-Term Deferred Tax (2009 - 2026)

United Therapeutics has disclosed Long-Term Deferred Tax across 18 years of filings, most recently posting $311.6 million for Q2 2026.

• In Q2 2026, Long-Term Deferred Tax fell 31.7% year-over-year to $311.6 million; the TTM figure through Jun 2026 stood at $311.6 million (down 31.7% YoY), while the FY2025 annual figure was $357.7 million, down 21.97% from the prior year.
• Long-Term Deferred Tax came in at $311.6 million for Q2 2026 at United Therapeutics, down from $335.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $458.4 million in Q4 2024 to a low of $271.8 million in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $357.6 million, with a median of $345.2 million recorded in 2025.
• Year-over-year, Long-Term Deferred Tax rose 25.12% in 2022 and slumped 31.7% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $327.7 million in 2022, then increased by 20.48% to $394.8 million in 2023, then gained by 16.11% to $458.4 million in 2024, then dropped by 21.97% to $357.7 million in 2025, then fell by 12.89% to $311.6 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $311.6 million in Q2 2026, $335.4 million in Q1 2026, and $357.7 million in Q4 2025.